In this project, a molecular signature based on genomics and metabolomics will be developed from liquid biopsies. This signature will allow to predict the response to radiotherapy and early relapse in patients with prostate cancer undergoing external radiotherapy (SBRT and IMRT).
Prostate cancer is the second most common cancer among men with 1.28 million cases diagnosed in 2018 in the world, 88.4% of which are diagnosed in developed countries. It is the sixth leading cause of cancer death in men, with the highest mortality in developing countries, and much higher morbidity in developed countries thanks to the extension of diagnostic methods and early detection.
Results obtained in this project will allow to predict the response to therapy, as well as to detect early relapse in prostate cancer.